At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 145 enrolled
Drug / intervention
Xenetix +1 moredrug
Likely dose
Xenetix 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Clinical Study of Xenetix 300 in Multislice Computed Tomography (CT) Pediatric Indications
In Brief
A Phase 4 clinical trial evaluating Xenetix and Visipaque for Diagnostic Imaging. Completed, enrolled 145 participants across 1 site.
Detailed Summary
This is a clinical study of Xenetix 300 in Multislice Computed Tomography (MSCT) in pediatric indications.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiagnostic Imaging
CountriesFrance
Collaborators--
Timeline
Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2006
First PostedJul 2006
Primary CompletionApr 2009
Study CompletionJun 2009
TodayJul 2026
First PostedJul 4, 2006
Enrollment StartMay 1, 2006
Primary CompletionApr 1, 2009
Study CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 20.0 years ago
Interventions
Xenetixdrug
300 mg of iodine/ml
Visipaquedrug
270 mg of iodine/ml